Physician profile
Carson D Seeber
NPI 1861740300
$1,531.98
in general payments reported to CMS, 2019-2025
26 companies · $383 in 2025
The $383 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $518 · 2020: $85.46 · 2021: $91.49 · 2022: $13.88 · 2023: $224 · 2024: $216 · 2025: $383.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $823.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $823.42 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $299.33 | 2019-2025 | Airsupra, Breztri, Farxiga |
| Pfizer INC. | $189.13 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $156.68 | 2019-2020 | |
| Glaxosmithkline, LLC. | $151.07 | 2019 | |
| Tandem Diabetes Care, INC. | $83.32 | 2023 | T:Slim X2 Insulin Pump With Control-Iq |
| Merck Sharp & Dohme LLC | $66.66 | 2019-2025 | Capvaxive |
| Exact Sciences Corporation | $61.38 | 2023-2024 | Cologuard Collection Kit |
| Abbvie INC. | $53.40 | 2021-2022 | |
| Neurocrine Biosciences, INC. | $50.05 | 2025 | |
| Janssen Pharmaceuticals, INC | $44.18 | 2019-2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $42.40 | 2023 | |
| Sanofi Pasteur INC. | $39.56 | 2023 | |
| Amgen INC. | $31.82 | 2019-2020 | |
| Otsuka America Pharmaceutical, INC. | $31.48 | 2023-2024 | Rexulti |
| Novo Nordisk INC | $25.66 | 2019-2021 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $23.42 | 2019-2020 | |
| Dexcom, INC. | $23.14 | 2025 | Dexcom G6 Transmitter |
| Teva Pharmaceuticals USA, INC. | $23.04 | 2024 | Austedo Xr |
| Novartis Pharmaceuticals Corporation | $21.63 | 2019 | |
| Xeris Pharmaceuticals, INC. | $19.14 | 2025 | Gvoke Hypopen |
| Abbott Laboratories | $18.18 | 2025 | Freestyle Libre 3 |
| Medtronic, INC. | $16.84 | 2025 | Minimed 780g |
| Organogenesis INC. | $16.49 | 2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $15.85 | 2024 | Trintellix |
| Astellas Pharma US INC | $14.44 | 2019 | |
| Phadia US INC. | $13.69 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Carson Seeber listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.